ArticleOncotarget2015
MicroRNA-506 suppresses tumor proliferation and metastasis in colon cancer by directly targeting the oncogene EZH2.
Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed.
- Therapeutic potential of microRNA-506 in cancer treatment: mechanisms and therapeutic implications.Frontiers in oncology · 2025Review
- 6-gingerol promotes apoptosis of ovarian cancer cells through miR-506/Gli3 signaling pathway activation.Frontiers in oncology · 2025Article
- Expression of Anoikis-Related Genes and Potential Biomarkers in Colon Cancer Based on RNA-seq and scRNA-seq.Applied biochemistry and biotechnology · 2024Article
- To Assess the Role of microRNA-451 in the Progression and Metastasis of Colorectal Cancer.Applied biochemistry and biotechnology · 2024Article
- Identification of GUCA2A and COL3A1 as prognostic biomarkers in colorectal cancer by integrating analysis of RNA-Seq data and qRT-PCR validation.Scientific reports · 2023Article
- Identification of m6A-related lncRNAs as prognostic signature within colon tumor immune microenvironment.Cancer reports (Hoboken, N.J.) · 2023Article
- MicroRNA-506 as a tumor suppressor in anaplastic thyroid carcinoma by regulation of WNT and NOTCH signaling pathways.Iranian journal of basic medical sciences · 2023Article
- Development of 5-FU-modified tumor suppressor microRNAs as a platform for novel microRNA-based cancer therapeutics.Molecular therapy : the journal of the American Society of Gene Therapy · 2022Article
- Effect of artificial skin membrane on the expression of miR-155 and miR-506-3p in patients with second-degree burns.Journal of clinical laboratory analysis · 2022Article
- The role of epigenetic modifications in Colorectal Cancer Metastasis.Clinical & experimental metastasis · 2022Review
- miR-503-5p inhibits colon cancer tumorigenesis, angiogenesis, and lymphangiogenesis by directly downregulating VEGF-A.Gene therapy · 2022Article
- MicroRNA-506-3p inhibits ovarian cancer metastasis by down-regulating the expression of EZH2.Journal of Cancer · 2022Article
- hsa‑miR‑15a‑5p inhibits colon cell carcinoma via targeting CCND1.Molecular medicine reports · 2021Article
- MicroRNA expression in inflammatory bowel disease-associated colorectal cancer.World journal of gastrointestinal oncology · 2021Review
- Role of miR-506 in ulcerative colitis associated with primary sclerosing cholangitis.Scientific reports · 2021Article
- Therapeutic Approaches for Metastases from Colorectal Cancer and Pancreatic Ductal Carcinoma.Pharmaceutics · 2021Review
- Post-translational modifications of EZH2 in cancer.Cell & bioscience · 2020Review
- EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.BMC cancer · 2020Article
- Small interfering RNA-mediated knockdown of KRT80 suppresses colorectal cancer proliferation.Experimental and therapeutic medicine · 2020Article
- Bioinformatics Analysis of Prognostic miRNA Signature and Potential Critical Genes in Colon Cancer.Frontiers in genetics · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Increasing evidence reveals that aberrant expression of microRNA contributes to the development and progression of colon cancer, but the roles of microRNA-506 (miR-506) in colon cancer remain elusive. Here, we demonstrated that miR-506 was down-regulated in colon cancer tissue and cells and that miR-506 expression was inversely correlated with EZH2 expression, tumor size, lymph node invasion, TNM stage and metastasis. A high level of miR-506 identified patients with a favorable prognosis. In vitro and in vivo experiments confirmed that miR-506 inhibits the proliferation and metastasis of colon cancer, and a luciferase reporter assay confirmed that EZH2 is a direct and functional target of miR-506 via the 3'UTR of EZH2. The restoration of EZH2 expression partially reversed the proliferation and invasion of miR-506-overexpressing colon cancer cells. Moreover, we confirmed that the miR-506-EZH2 axis inhibits proliferation and metastasis by activating/suppressing specific downstream tumor-associated genes and the Wnt/β-catenin signaling pathway. Taking together, our study sheds light on the role of miR-506 as a suppressor for tumor growth and metastasis and raises the intriguing possibility that miR-506 may serve as a new potential marker for monitoring and treating colon cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.